TY - JOUR
T1 - Cytokine profiles in mice with arthritis induced by anti-type II collagen monoclonal antibody plus lipopolysaccharide
AU - Shinohe, Ryuki
AU - Sato, Masao
AU - Takemura, Masao
AU - Shimizu, Katsuji
AU - Koishi, Hirohisa
AU - Tanaka, Ryo
AU - Saito, Kuniaki
AU - Seishima, Mitsuru
N1 - Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2008
Y1 - 2008
N2 - Background: Anti-cytokine therapy is an effective therapy for rheumatoid arthritis. To know the kinetics of cytokine expression, we investigated mice with arthritis induced by anti-type II collagen monoclonal antibody (anti-CII Abs) plus lipopolysaccharide (LPS). Methods: BALB/c mice (7 weeks' age) were injected i.v. with anti-CII Abs 2 mg/mouse and 3 days later injected i.p. with 50 μ g of LPS. Mice developed arthritis, and the cytokine expressions in extracted legs were determined by RT-PCR. Serum cytokine concentrations were measured using ELISA. In addition, both sets of data were compared with those of TNF gene-deficient mice. Results: After induction of arthritis in wild-type mice, mRNA expression of TNF-α increased early, followed by IL-18. IL-1β and IL-6 mRNA expressions rose comparatively later. TNF-α, IL-1β and IL-6 concentrations in the serum reflected the level of their mRNA expressions. Interestingly, serum IL-18 level showed two distinct peaks, at early and later phase. In contrast, arthritis did not develop in TNF-α-deficient mice, and no elevation of IL-β or IL-6 in either serum or tissue mRNA was observed at any time point. Further, no increase in tissue mRNA levels was seen in TNF-α -deficient mice, however, there was a significant increase in serum IL-18 concentrations in the later phase. Conclusion: This study demonstrates that mRNA levels of TNF-α and IL-18 in both serum and joint tissue are increased, in the early phase with different patterns in mice with arthritis induced by anti-CII Abs plus LPS; IL-1β and IL-6 levels also increased in the later phase. The results using TNF-α -deficient mice indicate that TNF-α might play a crucial role as a key upstream molecule in the cytokine network of early inflammatory arthritis, and that TNF-α might trigger the synthesis of several other cytokines.
AB - Background: Anti-cytokine therapy is an effective therapy for rheumatoid arthritis. To know the kinetics of cytokine expression, we investigated mice with arthritis induced by anti-type II collagen monoclonal antibody (anti-CII Abs) plus lipopolysaccharide (LPS). Methods: BALB/c mice (7 weeks' age) were injected i.v. with anti-CII Abs 2 mg/mouse and 3 days later injected i.p. with 50 μ g of LPS. Mice developed arthritis, and the cytokine expressions in extracted legs were determined by RT-PCR. Serum cytokine concentrations were measured using ELISA. In addition, both sets of data were compared with those of TNF gene-deficient mice. Results: After induction of arthritis in wild-type mice, mRNA expression of TNF-α increased early, followed by IL-18. IL-1β and IL-6 mRNA expressions rose comparatively later. TNF-α, IL-1β and IL-6 concentrations in the serum reflected the level of their mRNA expressions. Interestingly, serum IL-18 level showed two distinct peaks, at early and later phase. In contrast, arthritis did not develop in TNF-α-deficient mice, and no elevation of IL-β or IL-6 in either serum or tissue mRNA was observed at any time point. Further, no increase in tissue mRNA levels was seen in TNF-α -deficient mice, however, there was a significant increase in serum IL-18 concentrations in the later phase. Conclusion: This study demonstrates that mRNA levels of TNF-α and IL-18 in both serum and joint tissue are increased, in the early phase with different patterns in mice with arthritis induced by anti-CII Abs plus LPS; IL-1β and IL-6 levels also increased in the later phase. The results using TNF-α -deficient mice indicate that TNF-α might play a crucial role as a key upstream molecule in the cytokine network of early inflammatory arthritis, and that TNF-α might trigger the synthesis of several other cytokines.
UR - http://www.scopus.com/inward/record.url?scp=39349108580&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=39349108580&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:39349108580
SN - 0370-5633
VL - 37
SP - 53
EP - 62
JO - Japanese Journal of Clinical Chemistry
JF - Japanese Journal of Clinical Chemistry
IS - 1
ER -